Carole Ho, Chief Medical Officer at Denali Therapeutics Inc. (DNLI), sold 44,916 shares at $23.79 ($1.1M) on 2024-08-20, disclosed to the SEC on 2024-08-22.
Scheduled sale ($1.1M) by Chief Medical Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $23.79 | 2,453 | $58K | 5.3% |
| 2 | $23.79 | 2,453 | $58K | 5.3% |
| 3 | $24.41 | 14,098 | $344K | 31.3% |
| 4 | $24.41 | 14,098 | $344K | 31.3% |
| 5 | $24.96 | 5,907 | $147K | 13.4% |
| 6 | $24.96 | 5,907 |
| $147K |
| 13.4% |
| Total | $24.49 avg | 44,916 | $1.1M | 100% |
| Filing → |
| DNLI | SELL | 2024-08-15 | $107K | — | Filing → |
| DNLI | SELL | 2024-02-15 | $73K | — | Filing → |
| DNLI | SELL | 2024-01-12 | $178K | — | Filing → |